Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* On stable Food and Drug Administration (FDA)-approved antiretrovirals for at least 8 weeks~* Excess abdominal fat based on waist and hip measurements done at the screening visit. \[waist greater than 34.7 inches (men) or 29.6 inches (women) and waist to hip ratio greater than 0.95 (men) or 0.9 (women)\]~* Evidence of insulin resistance (based on fasting glucose and insulin levels done at screening)~* Triglycerides less than 750 mg/dL~Exclusion Criteria:~* Pregnancy~* Active AIDS-defining infection or other acute illness, within 30 days of entry.~* Active cancer (except for localized Kaposi's sarcoma) or active brain tumor~* Any diagnosis of pancreatitis, carpal tunnel syndrome, diabetes, angina, coronary artery disease, or disorder associated with fluid retention (examples: cirrhosis, congestive heart failure)~* Untreated or uncontrolled high blood pressure, within 30 days of entry.~* Within 12 weeks of study entry, use of the following:~  * Obesity (fat-reducing) drugs.~ * Anti-diabetic or insulin-sensitizing drugs (examples: rosiglitazone, pioglitazone, or metformin).~ * Systemic glucocorticoids (example: prednisone).~ * Growth hormone or any medication for AIDS-associated wasting.~ * Systemic chemotherapy, interferon, or radiation therapy.~ * Androgenic agents \[examples: nandrolone, oxandrolone (Oxandrin) (testosterone replacement therapy is permitted if started more than 30 days before entry)\]~ * Appetite stimulants (Marinol, Megace, Periactin).~* Use of cholesterol lowering drugs, unless started more than 12 weeks before entry~* Inability to have a magnetic resonance imaging (MRI) scan performed (examples: cardiac pacemaker, intracranial aneurysm clips)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- rhGH + rosi (Type: EXPERIMENTAL): Recombinant human growth hormone + rosiglitazone
- rhGH placebo + rosi (Type: EXPERIMENTAL): Placebo for recombinant human growth hormone + rosiglitazone
- rhGH + rosi placebo (Type: EXPERIMENTAL): Recombinant human growth hormone + placebo for rosiglitazone
- Double placebo (Type: PLACEBO_COMPARATOR): Placebo for recombinant human growth hormone + placebo for rosiglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).